

Keith D Lindor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7682195/publications.pdf>

Version: 2024-02-01

259
papers

29,464
citations

3325

91
h-index

5101

166
g-index

300
all docs

300
docs citations

300
times ranked

11483
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential Association of Doxycycline With the Onset of Primary Sclerosing Cholangitis: A Case Series. <i>American Journal of Therapeutics</i> , 2022, 29, e437-e443.	0.5	5
2	Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2022, 75, 1012-1013.	3.6	34
3	Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4170-4180.	1.1	3
4	Alan Hofmann (1931-2021): A career well spent understanding bile acids. <i>Hepatology</i> , 2022, 75, 238-239.	3.6	0
5	Machine learning in primary biliary cholangitis: A novel approach for risk stratification. <i>Liver International</i> , 2022, 42, 615-627.	1.9	7
6	A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis. <i>Hepatology Communications</i> , 2022, 6, 1589-1597.	2.0	7
7	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1688-1697.e14.	2.4	30
8	Successful response of primary sclerosing cholangitis and associated ulcerative colitis to oral vancomycin may depend on brand and personalized dose: report in an adolescent. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 684-689.	0.4	8
9	Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2021, 73, 1868-1881.	3.6	25
10	Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 53-66.	0.5	1
11	Safety of fibrates in cholestatic liver diseases. <i>Liver International</i> , 2021, 41, 1335-1343.	1.9	25
12	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2021, 116, 1514-1522.	0.2	14
13	Global incidence, prevalence and features of primary sclerosing cholangitis: A systematic review and meta-analysis. <i>Liver International</i> , 2021, 41, 2418-2426.	1.9	21
14	Liver Stiffness Measured by Either Magnetic Resonance or Transient Elastography Is Associated With Liver Fibrosis and Is an Independent Predictor of Outcomes Among Patients With Primary Biliary Cholangitis. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 449-457.	1.1	34
15	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	2.4	17
16	Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 90-109.	1.9	21
17	Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 941-950.	0.6	31
18	The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience. <i>Journal of Gastroenterology</i> , 2020, 55, 1087-1097.	2.3	10

#	ARTICLE	IF	CITATIONS
19	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.2	74
20	Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , 2020, 115, 262-270.	0.2	14
21	Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases. <i>Clinical Liver Disease</i> , 2020, 15, 1-2.	1.0	13
22	An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. <i>Journal of Gastroenterology</i> , 2020, 55, 523-532.	2.3	22
23	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , 2020, 69, 1502-1509.	6.1	28
24	Simplified care-pathway selection for nonspecialist practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	0.8	2
25	Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2019, 69, 394-419.	3.6	507
26	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1127-1136.	1.9	66
27	AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2416-2422.	2.4	60
28	Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 633-639.	0.6	23
29	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	2.4	54
30	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 357-365.	1.8	148
31	Current and promising therapy for primary biliary cholangitis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1161-1167.	0.9	10
32	NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter. <i>Journal of Hepatology</i> , 2019, 70, 348-350.	1.8	5
33	Cancer risk, screening and surveillance in primary sclerosing cholangitis. <i>Minerva Gastroenterologica E Dietologica</i> , 2019, 65, 214-228.	2.2	7
34	Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. <i>World Journal of Gastroenterology</i> , 2019, 25, 659-671.	1.4	75
35	Editorial: is proton pump inhibitor use associated with worse outcomes in patients with liver abscesses?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1226-1227.	1.9	1
36	Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2018, 68, 1174-1188.	3.6	42

#	ARTICLE	IF	CITATIONS
37	Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 886-895.	1.9	57
38	Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1342-1350.e1.	2.4	73
39	Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1333-1341.e6.	2.4	42
40	Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. <i>Liver International</i> , 2018, 38, 399-411.	1.9	30
41	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018, 113, 254-264.	0.2	64
42	Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. <i>Hepatology</i> , 2018, 67, 2338-2351.	3.6	92
43	Managing PBC: Expanding the Provider Comfort Zone. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2487-2488.	1.1	0
44	Primary sclerosing cholangitis in children versus adults: lessons for the clinic. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1025-1032.	1.4	11
45	Emerging therapeutic targets for primary sclerosing cholangitis. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 393-401.	0.5	0
46	Antimitochondrial Antibody-“Negative Primary Biliary Cholangitis. <i>Clinics in Liver Disease</i> , 2018, 22, 589-601.	1.0	11
47	Dominant strictures in primary sclerosing cholangitis: A multicenter survey of clinical definitions and practices. <i>Hepatology Communications</i> , 2018, 2, 836-844.	2.0	28
48	Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment. <i>Gastroenterology and Hepatology</i> , 2018, 14, 293-304.	0.2	9
49	Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance. <i>Gastroenterology and Hepatology</i> , 2018, 14, 427-432.	0.2	4
50	Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. <i>American Journal of Therapeutics</i> , 2017, 24, e56-e63.	0.5	55
51	A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis. <i>American Journal of Therapeutics</i> , 2017, 24, e167-e176.	0.5	46
52	Update on pharmacotherapies for cholestatic liver disease. <i>Hepatology Communications</i> , 2017, 1, 7-17.	2.0	16
53	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	0.6	355
54	Emerging treatments for primary sclerosing cholangitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 451-459.	1.4	12

#	ARTICLE	IF	CITATIONS
55	Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis. <i>Journal of Clinical Gastroenterology</i> , 2017, 51, e11-e16.	1.1	38
56	Old and new treatments for primary biliary cholangitis. <i>Liver International</i> , 2017, 37, 490-499.	1.9	37
57	Clinical implications of serial versus isolated biliary fluorescence <i>in situ</i> hybridization (FISH) polysomy in primary sclerosing cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 377-381.	0.6	26
58	An update on cancer risk and surveillance in primary sclerosing cholangitis. <i>Liver International</i> , 2017, 37, 1103-1109.	1.9	40
59	Heterogeneity of Outcomes Following Liver Transplantation for Primary Sclerosing Cholangitis: Age Matters. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3210-3211.	1.1	2
60	Investigational drugs in phase II clinical trials for primary biliary cholangitis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1115-1121.	1.9	6
61	Curcumin in Hepatobiliary Disease: Pharmacotherapeutic Properties and Emerging Potential Clinical Applications. <i>Annals of Hepatology</i> , 2017, 16, 835-841.	0.6	39
62	Ursodeoxycholic Acid Treatment in Primary Sclerosing Cholangitis. , 2017, , 145-152.		7
63	Oral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis. <i>Pediatric Gastroenterology, Hepatology and Nutrition</i> , 2016, 19, 210.	0.4	18
64	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. <i>Hepatology</i> , 2016, 64, 189-199.	3.6	101
65	Novel treatments in primary sclerosing cholangitis. <i>Clinical Liver Disease</i> , 2016, 8, 132-135.	1.0	1
66	The Microbiome and Primary Sclerosing Cholangitis. <i>Seminars in Liver Disease</i> , 2016, 36, 340-348.	1.8	15
67	Targets and investigative treatments for primary biliary cholangitis. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1011-1020.	0.5	0
68	Advances in primary sclerosing cholangitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 68-77.	3.7	18
69	Obeticholic acid for the treatment of primary biliary cholangitis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1809-1815.	0.9	39
70	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016, 375, 631-643.	13.9	817
71	Distinguishing immunoglobulin G4-related disease from its pancreatobiliary mimics: Are we there now?. <i>Hepatology</i> , 2016, 64, 340-343.	3.6	11
72	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	6.1	139

#	ARTICLE	IF	CITATIONS
73	Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 745-752.	0.6	36
74	Emerging drugs for the treatment of Primary Biliary Cholangitis. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 39-56.	1.0	16
75	The management of autoimmunity in patients with cholestatic liver diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 73-91.	1.4	12
76	Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. <i>Annals of Hepatology</i> , 2016, 15, 246-53.	0.6	39
77	Editorial: betaretrovirus in biliary epithelia of patients with autoimmune and cryptogenic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 490-490.	1.9	3
78	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Hepatology</i> , 2015, 62, 1620-1622.	3.6	125
79	Current research on the treatment of primary sclerosing cholangitis. <i>Intractable and Rare Diseases Research</i> , 2015, 4, 1-6.	0.3	26
80	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, e57-e59.	0.7	36
81	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. <i>Gastroenterology</i> , 2015, 148, 751-761.e8.	0.6	470
82	Novel therapeutic targets in primary biliary cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 147-158.	8.2	110
83	Primary biliary cirrhosis: safety and benefits of established and emerging therapies. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1435-1444.	1.0	8
84	ACG Clinical Guideline: Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2015, 110, 646-659.	0.2	400
85	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	0.6	330
86	Changing nomenclature for PBC: From "cirrhosis" to "cholangitis". <i>Journal of Hepatology</i> , 2015, 63, 1285-1287.	1.8	85
87	Primary biliary cirrhosis. <i>Lancet</i> , The, 2015, 386, 1565-1575.	6.3	502
88	Unmet clinical need in autoimmune liver diseases. <i>Journal of Hepatology</i> , 2015, 62, 208-218.	1.8	56
89	Recent advances in the development of farnesoid X receptor agonists. <i>Annals of Translational Medicine</i> , 2015, 3, 5.	0.7	115
90	Commentary: Primary Sclerosing Cholangitis. , 2015, , 61-63.		0

#	ARTICLE	IF	CITATIONS
91	Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. <i>Annals of Hepatology</i> , 2014, 13, 384-389.	0.6	14
92	Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 901-908.	0.6	77
93	The Natural History of Primary Biliary Cirrhosis. <i>Seminars in Liver Disease</i> , 2014, 34, 329-333.	1.8	33
94	An overview of current and future therapeutic strategies for the treatment of primary sclerosing cholangitis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 545-556.	0.5	1
95	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	0.6	365
96	Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?). <i>Hepatology</i> , 2014, 60, 785-788.	3.6	40
97	Low risk of HCC in patients who have PSC and cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 276-277.	8.2	8
98	Neoplasia in the ileoanal pouch following colectomy in patients with ulcerative colitis and primary sclerosing cholangitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1294-1299.	0.6	23
99	Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 365-372.	0.9	38
100	Primary biliary cirrhosis in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 427-433.	1.4	31
101	Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. <i>Annals of Hepatology</i> , 2014, 13, 384-9.	0.6	7
102	Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management. <i>Gastroenterology</i> , 2013, 145, 521-536.	0.6	359
103	Primary sclerosing cholangitis. <i>Lancet, The</i> , 2013, 382, 1587-1599.	6.3	484
104	Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis – a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 604-612.	1.9	212
105	Clinical management of autoimmune biliary diseases. <i>Journal of Autoimmunity</i> , 2013, 46, 88-96.	3.0	18
106	Primary sclerosing cholangitis: a review and update on therapeutic developments. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 103-114.	1.4	55
107	Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis. <i>BioMed Research International</i> , 2013, 2013, 1-7.	0.9	79
108	Likelihood of Malignancy in Gallbladder Polyps and Outcomes Following Cholecystectomy in Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2012, 107, 431-439.	0.2	77

#	ARTICLE	IF	CITATIONS
109	Long-term Outcomes of Patients With Primary Biliary Cirrhosis and Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 182-185.	2.4	24
110	Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. <i>Liver International</i> , 2012, 32, 790-795.	1.9	62
111	The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis – a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 255-265.	1.9	37
112	Pathogenesis and management of pruritus in cholestatic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1150-1158.	1.4	50
113	Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. <i>Hepatology</i> , 2012, 55, 512-521.	3.6	130
114	Challenges of Cholangiocarcinoma Detection in Patients with Primary Sclerosing Cholangitis. <i>Journal of Analytical Oncology</i> , 2012, 1, 50-55.	0.1	20
115	Recent developments in the management of idiopathic cholestatic liver disease. <i>Annals of Gastroenterology</i> , 2012, 25, 317-326.	0.4	1
116	Colon Neoplasms Develop Early in the Course of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 52-56.	2.4	53
117	Bone Disease in Patients With Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2011, 140, 180-188.	0.6	102
118	Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , 2011, 43, 309-313.	0.4	138
119	Many Patients With Primary Sclerosing Cholangitis and Increased Serum Levels of Carbohydrate Antigen 19-9 Do Not Have Cholangiocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 434-439.e1.	2.4	108
120	Varices in Early Histological Stage Primary Biliary Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, e66-e71.	1.1	40
121	Antibiotics for the Treatment of Primary Sclerosing Cholangitis. <i>American Journal of Therapeutics</i> , 2011, 18, 261-265.	0.5	24
122	Primary Sclerosing Cholangitis Associated with Elevated ImmunoglobulinG4: Clinical Characteristics and Response to Therapy. <i>American Journal of Therapeutics</i> , 2011, 18, 198-205.	0.5	119
123	High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1185-1192.	1.9	75
124	Cancer surveillance in patients with primary sclerosing cholangitis. <i>Hepatology</i> , 2011, 54, 1842-1852.	3.6	248
125	High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2011, 106, 1638-1645.	0.2	223
126	New Treatment Strategies for Primary Sclerosing Cholangitis. <i>Digestive Diseases</i> , 2011, 29, 113-116.	0.8	15

#	ARTICLE	IF	CITATIONS
127	Primary Sclerosing Cholangitis Patients With Serial Polysomy Fluorescence In Situ Hybridization Results Are at Increased Risk of Cholangiocarcinoma. <i>American Journal of Gastroenterology</i> , 2011, 106, 2023-2028.	0.2	101
128	Pregnancy in primary sclerosing cholangitis. <i>Gut</i> , 2011, 60, 1027-1028.	6.1	3
129	Moexipril for Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid. <i>Digestive Diseases and Sciences</i> , 2010, 55, 476-483.	1.1	11
130	Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. <i>Hepatology</i> , 2010, 51, 174-180.	3.6	159
131	Reply: Diagnostic Utility of Chromosome 17 and p16 Abnormalities in Fluorescence In Situ Hybridization Tests in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2010, 52, 394-395.	3.6	0
132	Fatigue measurements in patients with primary biliary cirrhosis and the risk of mortality during follow-up. <i>Liver International</i> , 2010, 30, 251-258.	1.9	25
133	The possible link between the thyroid and autoimmune liver diseases: reply. <i>Liver International</i> , 2010, 30, 1240-1241.	1.9	1
134	Autoimmune Hepatitisâ€PBC Overlap Syndrome: A Simplified Scoring System May Assist in the Diagnosis. <i>American Journal of Gastroenterology</i> , 2010, 105, 345-353.	0.2	99
135	Fatigue in primary biliary cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 313-319.	8.2	37
136	Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis?. <i>Translational Research</i> , 2010, 155, 120-122.	2.2	2
137	Linking medical education and patient care. <i>Minnesota Medicine</i> , 2010, 93, 32, 34.	0.1	0
138	Minocycline in the Treatment of Patients With Primary Sclerosing Cholangitis: Results of a Pilot Study. <i>American Journal of Gastroenterology</i> , 2009, 104, 83-88.	0.2	114
139	Primary biliary cirrhosis. <i>Hepatology</i> , 2009, 50, 291-308.	3.6	1,020
140	High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. <i>Hepatology</i> , 2009, 50, 808-814.	3.6	603
141	B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor- β^2 receptor II dominant negative mice. <i>Hepatology</i> , 2009, 50, 1893-1903.	3.6	88
142	Review article: nuclear receptors and liver disease â€ current understanding and new therapeutic implications. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 816-825.	1.9	15
143	Silymarin in the Treatment of Patients with Primary Sclerosing Cholangitis: An Open-Label Pilot Study. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1716-1720.	1.1	38
144	Conflict of interest policy. <i>Liver Transplantation</i> , 2008, 14, 1-1.	1.3	11

#	ARTICLE	IF	CITATIONS
145	Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. <i>Hepatology</i> , 2008, 48, 1106-1117.	3.6	329
146	Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2008, 48, 1149-1156.	3.6	62
147	Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 886-894.	1.9	52
148	Immunoglobulin G4-associated Cholangitis: Clinical Profile and Response to Therapy. <i>Gastroenterology</i> , 2008, 134, 706-715.	0.6	807
149	Antimitochondrial Antibody-negative Primary Biliary Cirrhosis. <i>Gastroenterology Clinics of North America</i> , 2008, 37, 479-484.	1.0	35
150	Clinical features and management of primary sclerosing Cholangitis. <i>World Journal of Gastroenterology</i> , 2008, 14, 3338.	1.4	50
151	Primary sclerosing cholangitis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008, 22, 689-698.	1.8	73
152	Overlap of Autoimmune Hepatitis and Primary Biliary Cirrhosis: Long-Term Outcomes. <i>American Journal of Gastroenterology</i> , 2007, 102, 1244-1250.	0.2	139
153	Ursodeoxycholic Acid for the Treatment of Primary Biliary Cirrhosis. <i>New England Journal of Medicine</i> , 2007, 357, 1524-1529.	13.9	98
154	Clinical Predictors for Hepatocellular Carcinoma in Patients With Primary Biliary Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 259-264.	2.4	51
155	Immunoglobulin G4 associated cholangitis: Description of an emerging clinical entity based on review of the literature. <i>Hepatology</i> , 2007, 45, 1547-1554.	3.6	224
156	Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. <i>Hepatology</i> , 2007, 46, 785-792.	3.6	125
157	Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. <i>Hepatology</i> , 2007, 47, 133-142.	3.6	35
158	Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 1236-1245.	1.3	159
159	Development of autoimmune hepatitis in primary biliary cirrhosis. <i>Liver International</i> , 2007, 27, 1086-1090.	1.9	51
160	Fluoxetine for the Treatment of Fatigue in Primary Biliary Cirrhosis: A Randomized, Double-Blind Controlled Trial. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1985-1991.	1.1	46
161	Elevated Serum IgG4 Concentration in Patients with Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2006, 101, 2070-2075.	0.2	327
162	Mycophenolate Mofetil for the Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 838.	1.1	41

#	ARTICLE	IF	CITATIONS
163	Primary Sclerosing Cholangitis. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 62-72.	0.9	112
164	Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo-controlled trial. <i>Hepatology</i> , 2005, 42, 762-771.	3.6	138
165	Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview-based study of 1032 patients. <i>Hepatology</i> , 2005, 42, 1194-1202.	3.6	560
166	The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis. <i>Digestive Diseases and Sciences</i> , 2005, 50, 1734-1740.	1.1	300
167	Mycophenolate Mofetil for the Treatment of Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2005, 100, 308-312.	0.2	69
168	Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 168-71.	1.1	28
169	Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2004, 99, 523-526.	0.2	503
170	Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. <i>Hepatology</i> , 2004, 39, 770-778.	3.6	651
171	Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. <i>Hepatology</i> , 2004, 40, 39-45.	3.6	117
172	Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 1116-1122.	2.4	74
173	Primary sclerosing cholangitis in children: A long-term follow-up study. <i>Hepatology</i> , 2003, 38, 210-217.	3.6	218
174	Medical treatment for primary sclerosing cholangitis: Risk versus benefit. <i>Hepatology</i> , 2003, 32, 871-872.	3.6	5
175	Natural history of pruritus in primary biliary cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 297-302.	2.4	112
176	When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 89-95.	2.4	84
177	Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. <i>Clinics in Liver Disease</i> , 2003, 7, 901-910.	1.0	38
178	Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. <i>Gastroenterology</i> , 2003, 124, 889-893.	0.6	534
179	Primary biliary cirrhosis. <i>Lancet, The</i> , 2003, 362, 53-61.	6.3	306
180	Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2003, 39, 12-16.	1.8	199

#	ARTICLE	IF	CITATIONS
181	Is There A Role for Liver Biopsy in Primary Sclerosing Cholangitis?. American Journal of Gastroenterology, 2003, 98, 1155-1158.	0.2	146
182	Treatment With Ursodeoxycholic Acid Is Associated With Weight Gain in Patients With Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2003, 37, 183-185.	1.1	36
183	In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. American Journal of Gastroenterology, 2002, 97, 1138-1142.	0.2	175
184	Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. American Journal of Gastroenterology, 2002, 97, 1191-1197.	0.2	120
185	Pregnancy in a Patient With Primary Sclerosing Cholangitis. Journal of Clinical Gastroenterology, 2002, 35, 353-355.	1.1	27
186	Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. Journal of Hepatology, 2002, 36, 8-13.	1.8	42
187	Pirfenidone in the treatment of primary sclerosing cholangitis. Digestive Diseases and Sciences, 2002, 47, 157-161.	1.1	53
188	Primary biliary cirrhosis with additional features of autoimmune hepatitis: Response to therapy with ursodeoxycholic acid. Hepatology, 2002, 35, 409-413.	3.6	160
189	Small-duct primary sclerosing cholangitis: A long-term follow-up study. Hepatology, 2002, 35, 1494-1500.	3.6	189
190	Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. Journal of Hepatology, 2001, 35, 316-323.	1.8	170
191	Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Digestive Diseases and Sciences, 2001, 46, 2347-2352.	1.1	136
192	Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?. American Journal of Gastroenterology, 2001, 96, 3152-3157.	0.2	38
193	High-Dose Ursodeoxycholic Acid as a Therapy for Patients With Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2001, 96, 1558-1562.	0.2	215
194	Balloon Dilation Compared To Stenting of Dominant Strictures in Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2001, 96, 1059-1066.	0.2	193
195	Fat-soluble vitamin levels in patients with primary biliary cirrhosis. American Journal of Gastroenterology, 2001, 96, 2745-2750.	0.2	106
196	A Revised Natural History Model for Primary Sclerosing Cholangitis. Mayo Clinic Proceedings, 2000, 75, 688-694.	1.4	285
197	Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology, 2000, 31, 318-323.	3.6	171
198	Silymarin in the Treatment of Patients With Primary Biliary Cirrhosis With a Suboptimal Response to Ursodeoxycholic Acid. Hepatology, 2000, 32, 897-900.	3.6	80

#	ARTICLE	IF	CITATIONS
199	Reliability and Validity of the NIDDK-QA Instrument in the Assessment of Quality of Life in Ambulatory Patients With Cholestatic Liver Disease. <i>Hepatology</i> , 2000, 32, 924-929.	3.6	45
200	Metabolic and nutritional considerations in nonalcoholic fatty liver. <i>Hepatology</i> , 2000, 32, 3-10.	3.6	166
201	Management of primary biliary cirrhosis: From diagnosis to end-stage disease. <i>Current Gastroenterology Reports</i> , 2000, 2, 94-98.	1.1	5
202	Medical Management of Chronic Cholestatic Liver Diseases. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2000, 14, 93D-98D.	1.8	1
203	A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. <i>American Journal of Gastroenterology</i> , 2000, 95, 2338-2342.	0.2	85
204	Oral budesonide in the treatment of primary sclerosing cholangitis. <i>American Journal of Gastroenterology</i> , 2000, 95, 2333-2337.	0.2	138
205	A Revised Natural History Model for Primary Sclerosing Cholangitis. <i>Mayo Clinic Proceedings</i> , 2000, 75, 688-694.	1.4	280
206	Epidemiology and natural history of primary biliary cirrhosis in a U.S. community. <i>Gastroenterology</i> , 2000, 119, 1631-1636.	0.6	321
207	Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. <i>Journal of Hepatology</i> , 2000, 33, 537-542.	1.8	152
208	Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. <i>Journal of Hepatology</i> , 2000, 33, 878-882.	1.8	75
209	Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. <i>Journal of Hepatology</i> , 2000, 33, 537-542.	1.8	157
210	Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. <i>Liver International</i> , 1999, 19, 115-121.	1.9	168
211	Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. <i>Digestive Diseases and Sciences</i> , 1999, 44, 602-607.	1.1	70
212	Primary biliary cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 1999, 2, 473-480.	0.3	3
213	Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. <i>Hepatology</i> , 1999, 29, 39-43.	3.6	79
214	Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. <i>Hepatology</i> , 1999, 29, 644-647.	3.6	209
215	Incidence of cancer in primary biliary cirrhosis: The mayo experience. <i>Hepatology</i> , 1999, 29, 1396-1398.	3.6	97
216	The relative role of the child-pugh classification and the mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. <i>Hepatology</i> , 1999, 29, 1643-1648.	3.6	124

#	ARTICLE	IF	CITATIONS
217	Primary sclerosing cholangitis. <i>Hepatology</i> , 1999, 30, 325-332.	3.6	245
218	Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial. <i>Hepatology</i> , 1999, 30, 1381-1386.	3.6	133
219	Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 1999, 30, 1356-1362.	3.6	1,453
220	Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. <i>Liver Transplantation</i> , 1999, 5, 269-274.	1.9	25
221	Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. <i>Journal of Hepatology</i> , 1999, 30, 830-835.	1.8	112
222	Cost-effectiveness of ultrasound-guided liver biopsy. <i>Hepatology</i> , 1998, 27, 1220-1226.	3.6	150
223	Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. <i>Journal of Hepatology</i> , 1998, 29, 729-735.	1.8	119
224	Ursodiol for Primary Sclerosing Cholangitis. <i>New England Journal of Medicine</i> , 1997, 336, 691-695.	13.9	569
225	Interactions Between Chronic Liver Disease and Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 1997, 3, 288-302.	0.9	54
226	Ursodeoxycholic Acid Delays the Onset of Esophageal Varices in Primary Biliary Cirrhosis. <i>Mayo Clinic Proceedings</i> , 1997, 72, 1137-1140.	1.4	149
227	Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. <i>Gastroenterology</i> , 1997, 113, 884-890.	0.6	608
228	REVIEW: Nonalcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 398-403.	1.4	198
229	Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. <i>Hepatology</i> , 1997, 26, 22-26.	3.6	100
230	Early primary biliary cirrhosis: Just delayed or different?. <i>Hepatology</i> , 1997, 26, 239-241.	3.6	14
231	Interactions between chronic liver disease and inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 1997, 3, 288-302.	0.9	58
232	Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. <i>Gastroenterology</i> , 1996, 110, 1515-1518.	0.6	209
233	Time course of histological progression in primary biliary cirrhosis. <i>Hepatology</i> , 1996, 23, 52-56.	3.6	171
234	Time course of histological progression in primary biliary cirrhosis. <i>Hepatology</i> , 1996, 23, 52-56.	3.6	6

#	ARTICLE	IF	CITATIONS
235	Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. American Journal of Gastroenterology, 1996, 91, 511-5.	0.2	66
236	Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. American Journal of Gastroenterology, 1996, 91, 2314-7.	0.2	27
237	Serum Lipid and Fat-Soluble Vitamin Levels in Primary Sclerosing Cholangitis. Journal of Clinical Gastroenterology, 1995, 20, 215-219.	1.1	83
238	Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference?. Hepatology, 1995, 21, 389-392.	3.6	95
239	The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study. Hepatology, 1995, 22, 1158-1162.	3.6	58
240	Characterisation of patients with a complete biochemical response to ursodeoxycholic acid.. Gut, 1995, 36, 935-938.	6.1	68
241	The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study*1. Hepatology, 1995, 22, 1158-1162.	3.6	81
242	Colchicine and ursodeoxycholic acid for primary biliary cirrhosis: Emerging results. Gastroenterology, 1995, 108, 1592-1594.	0.6	3
243	Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?. Hepatology, 1995, 21, 389-92.	3.6	90
244	Antimitochondrial antibody-negative primary biliary cirrhosis. American Journal of Gastroenterology, 1995, 90, 247-9.	0.2	127
245	Primary biliary cirrhosis. Revista De GastroenterologÃa De MÃ©xico, 1995, 60, S75-7.	0.4	0
246	Primary sclerosing cholangitis. Revista De GastroenterologÃa De MÃ©xico, 1995, 60, S78-80.	0.4	0
247	Chronic cholestasis in a young man. Hepatology, 1994, 20, 1351-1355.	3.6	7
248	Effect of Ursodeoxycholic Acid on Serum Lipids of Patients With Primary Biliary Cirrhosis. Mayo Clinic Proceedings, 1994, 69, 923-929.	1.4	43
249	Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology, 1994, 106, 1284-1290.	0.6	457
250	Chronic cholestasis in a young man. Hepatology, 1994, 20, 1351-1355.	3.6	3
251	The natural history of abdominal pain associated with primary biliary cirrhosis. American Journal of Gastroenterology, 1994, 89, 1840-3.	0.2	23
252	Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: What is the risk?. Hepatology, 1992, 15, 858-862.	3.6	168

#	ARTICLE	IF	CITATIONS
253	The metabolic bone disease of primary sclerosing cholangitis. <i>Hepatology</i> , 1991, 14, 257-261.	3.6	115
254	The metabolic bone disease of primary sclerosing cholangitis. <i>Hepatology</i> , 1991, 14, 257-261.	3.6	7
255	The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. <i>American Journal of Gastroenterology</i> , 1991, 86, 57-61.	0.2	88
256	A Controlled Trial of Cyclosporine in the Treatment of Primary Biliary Cirrhosis. <i>New England Journal of Medicine</i> , 1990, 322, 1419-1424.	13.9	208
257	Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis. <i>Hepatology</i> , 1988, 8, 668-676.	3.6	60
258	The autologous mixed lymphocyte reaction in primary biliary cirrhosis: Analysis of activation and blastogenesis of autoreactive T lymphocytes. <i>Hepatology</i> , 1988, 8, 1555-1559.	3.6	16
259	Enhanced autoreactivity of T-lymphocytes in primary sclerosing cholangitis. <i>Hepatology</i> , 1987, 7, 884-888.	3.6	60